ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients

Transplantation. 2006 Feb 15;81(3):463-8. doi: 10.1097/01.tp.0000185305.63759.d3.

Abstract

Background: Chronic renal failure (CRF) is a major cause of morbidity and mortality after orthotopic liver transplantation (OLTX) and is predominantly caused by calcineurin inhibitors (CI)-induced nephrotoxicity. The activation of the renin angiotensin system (RAS) has been implicated in the pathogenesis of chronic nephrotoxicity from CI.

Methods: We retrospectively investigated the genes coding for components of the RAS (ACE gene, Angiotensin II receptor 1 gene, Angiotensinogen gene) in 233 liver transplant recipients receiving Cyclosporine (CsA) or Tacrolimus (Tac) as maintenance immunosuppressant. All patients with serum creatinine (sCr) <1.0 mg/dL (n=143) before orthotopic liver transplantation (OLTX) were included in the final analysis. Patients were than categorized into two groups based upon their most recent postliver transplant sCr level: Group 1 (n=83) with sCr <1.5 mg/dL (mean 1.1+/-0.2) and group 2 (n=60) with sCr > or =1.5 mg/dL (mean 2.5+/-1.3)

Results: ACE D/D genotype was found in 57% of patients with sCr > or =1.5 mg/dL compared to 20% of patients with sCr <1.5 mg/dL (P<0.0001)

Conclusions: Our analysis strongly suggests that liver transplant patients with ACE gene D/D genotype are at a significant higher risk of developing CI-induced chronic nephrotoxicity.

MeSH terms

  • Angiotensinogen / genetics
  • Calcineurin Inhibitors*
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects*
  • Female
  • Genotype
  • Graft Rejection / drug therapy
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Kidney Failure, Chronic / chemically induced*
  • Kidney Failure, Chronic / genetics
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A / genetics*
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 2 / genetics
  • Risk Factors
  • Tacrolimus / administration & dosage
  • Tacrolimus / adverse effects*

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Angiotensinogen
  • Cyclosporine
  • ACE protein, human
  • Peptidyl-Dipeptidase A
  • Tacrolimus